CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells. - sprookjes - yvandenbroek - TriplyDB

CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells.

CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells.

http://www.wikidata.org/entity/Q37176556

about

Elotuzumab for the treatment of multiple myeloma Innovative agents in multiple myeloma Novel immunotherapies Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells Time to recurrence and survival in serous ovarian tumors predicted from integrated genomic profiles.Distinct gene expression profiles in subsets of chronic lymphocytic leukemia expressing stereotyped IGHV4-34 B-cell receptors.New insights, recent advances, and current challenges in the biological treatment of multiple myeloma.Antibody-based therapies in multiple myeloma Therapeutic monoclonal antibodies for multiple myeloma: an update and future perspectives.Profile of elotuzumab and its potential in the treatment of multiple myeloma Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo The molecular characterization and clinical management of multiple myeloma in the post-genome era.CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma Humoral immunotherapy of multiple myeloma: perspectives and perplexities.Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions.Monoclonal antibody-based immunotherapy for multiple myeloma.Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma.Association of Chromosomal Translocation and MiRNA Expression with The Pathogenesis of Multiple Myeloma.T cell-based targeted immunotherapies for patients with multiple myeloma.Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.Daratumumab and its potential in the treatment of multiple myeloma: overview of the preclinical and clinical development.The prospects and promise of chimeric antigen receptor immunotherapy in multiple myeloma.Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.Efficacy and safety of elotuzumab for the treatment of multiple myeloma.CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma.Altered expression of signalling lymphocyte activation molecule (SLAM) family receptors CS1 (CD319) and 2B4 (CD244) in patients with systemic lupus erythematosus.Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies.New recurrent chromosome alterations in patients with multiple myeloma and plasma cell leukemia.

P2860

Q26740278-5491831B-B819-446B-8A4B-47F3C9C0DCB1 Q27022493-1420B18E-EECD-44B6-983D-AAC2C85DDDDC Q33822677-4C59E122-CC33-4371-BAC9-AD177B8C11A1 Q33992425-DA1C7075-A539-40AC-82F0-23D739BAAC5C Q34071483-D86D8E25-5F83-48DE-9B40-90AC98CC00B6 Q34371084-A634DF49-959C-4AD7-B322-B0801D152AF0 Q34773850-E4040CC1-381F-4AFC-9CEE-0BB2F589ADB7 Q35431150-DBEE7D43-FCEA-4945-9364-56E0C470B14A Q35514038-14DFEFDC-22A8-43D9-B2BB-D893E9208097 Q35628678-37742CCC-065F-461D-8991-4F6CAA4E0B9D Q36162685-8769F162-D521-44A3-A9CB-548C06A5A979 Q36939043-F059FC1F-E082-465F-8759-95BA273C8EAC Q37666309-2BEA39CA-6F88-4FFD-9312-5B66117A7D40 Q37724368-A9AF7FF0-1668-420D-B958-F46CEDBE7687 Q38014834-FEA1C2AC-CCC8-4F87-94ED-43DE4A0C4D22 Q38050507-989B6F9B-1A8A-4C1C-91CA-C832284F1685 Q38090691-58CDDE95-3713-4D06-B062-EFC062B4D819 Q38190971-D26E63B7-87C1-4FAA-9D68-7FA1FFBB06B5 Q38246639-A5855F07-77F5-4631-953A-C92564A1D26E Q38534837-94CFE5BE-0FED-4591-84E2-BBA5CC0C4997 Q38542091-36A6A6F4-9F60-4B75-B0FC-30C700D6FE24 Q38764944-D79C600C-7BB3-46E4-A326-7D68AE08B0AD Q38809499-FF8F9A3E-9094-4F1E-93B5-0DB372E3758B Q39070515-8E1C167A-B0B6-45F4-A57F-0EB081162D91 Q41547582-0D8DADFD-A607-469C-B20B-95F47310F169 Q43117312-30D4FC09-5226-4BDB-9D91-F55BE3AAC989 Q48255324-AC4F8477-64C0-43D3-8257-B7E47C835658 Q54084923-9DD7A16F-9A8F-4AAF-9D88-E98A010C7DE2

P2860

CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells.

http://www.wikidata.org/entity/Q37176556

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 04 February 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

CS1 promotes multiple myeloma ...... ith bone marrow stromal cells.

@en

CS1 promotes multiple myeloma ...... ith bone marrow stromal cells.

@nl

type

label

CS1 promotes multiple myeloma ...... ith bone marrow stromal cells.

@en

CS1 promotes multiple myeloma ...... ith bone marrow stromal cells.

@nl

prefLabel

CS1 promotes multiple myeloma ...... ith bone marrow stromal cells.

@en

CS1 promotes multiple myeloma ...... ith bone marrow stromal cells.

@nl

P1433

Q37176556-E257D325-6A86-4B0A-97B2-E2A510F09313

P1476

Q37176556-7D6365F4-5DD1-4999-BA1C-43D17CC8DC78

P2093

Q37176556-0B573243-8A19-4C53-9324-729C58E6CB13

Q37176556-1A32BFBE-64F5-45F1-A803-4FD1CD4EBE8E

Q37176556-36F185D8-71BB-4FBB-9BE2-2009B50E650B

Q37176556-4BBB93A9-FB6D-4A2A-84AC-15FDFFF9D90D

Q37176556-509C8750-D4B5-43FF-BE0A-D745EEDC7B4B

Q37176556-75AE2A02-839C-47F2-B2A8-26728FD748A0

Q37176556-811E8E9E-5EFF-4D35-BA2C-9EDC97A15CED

Q37176556-83165862-E598-494C-9E00-55AF9FBE8076

Q37176556-9024CE06-DA86-421A-BB00-61BA6B100CD5

Q37176556-91F9FC0F-B860-420E-94EB-31073602F11C

P2860

Q37176556-06347BB8-344F-4265-9474-8BDAD85E44CF

Q37176556-06EDBAEB-0648-4E57-8F9B-A94E66D809DE

Q37176556-08FB2A43-39DB-4998-A3A5-C4AC632D1DB4

Q37176556-1AEE2BC1-32D0-49DE-98AD-702A1548E3F7

Q37176556-20C1432A-A35F-4802-A3A3-0EF802586ED1

Q37176556-20E7CA11-DA06-4B7D-90AE-8B075178A3BB

Q37176556-265E9DA9-55CB-4F2A-AE0D-3624532F485C

Q37176556-2849168B-13CB-4065-9875-FDE52426965E

Q37176556-290D56D1-7A87-4CA1-90DF-CEF4F3B6DB21

Q37176556-2C3F996A-DCBC-4674-B29A-B58BAD51EADE

P304

Q37176556-75E8C1BE-8FD8-468B-8764-97AC9C05430A

P31

Q37176556-69E55F1B-B482-457C-9A5B-3DC016F0F914

P356

Q37176556-F88E49B6-93C9-4287-8731-AFCF3AFF5334

P407

Q37176556-AAF94D5B-8ECC-404C-9D6F-F5234D2B6F4E

P433

Q37176556-2FF0350B-95FE-452A-9274-CC2DFAFC9AEC

P478

Q37176556-982D0F72-3D54-4722-B428-6A15104C25A3

P50

Q37176556-4855CA66-AC8C-49FF-A7E0-DF77F34CB4C2

P577

Q37176556-55CA707A-5764-4AB1-8FB7-E6CE0B43E304

P5875

Q37176556-3E9E9EEB-C702-4959-BC26-72750C9DA288

P698

Q37176556-31625ADE-5AD8-4D92-88BD-993B3F2A6756

P932

Q37176556-2C7AC0D5-E16C-47E1-B678-9327A538C7FF

P356

BLOOD-2008-10-183772

P1433

P1476

CS1 promotes multiple myeloma ...... ith bone marrow stromal cells.

@en

P2093

Daniel E H Afar

http://www.w3.org/2001/XMLSchema#string

Ender Soydan

http://www.w3.org/2001/XMLSchema#string

Fangxin Hong

http://www.w3.org/2001/XMLSchema#string

Giovanni Tonon

http://www.w3.org/2001/XMLSchema#string

Kenneth C Anderson

http://www.w3.org/2001/XMLSchema#string

Klaus Podar

http://www.w3.org/2001/XMLSchema#string

Mariateresa Fulciniti

http://www.w3.org/2001/XMLSchema#string

Matthew J Rumizen

http://www.w3.org/2001/XMLSchema#string

Nikhil C Munshi

http://www.w3.org/2001/XMLSchema#string

Peter Burger

http://www.w3.org/2001/XMLSchema#string

P2860

Bioconductor: open software development for computational biology and bioinformatics

A novel immunoglobulin superfamily receptor (19A) related to CD2 is expressed on activated lymphocytes and promotes homotypic B-cell adhesion

Summaries of Affymetrix GeneChip probe level data

CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms

Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma

Overexpression of c-Maf contributes to T-cell lymphoma in both mice and human

CS1, a novel member of the CD2 family, is homophilic and regulates NK cell function

A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen

Molecular cloning of CS1, a novel human natural killer cell receptor belonging to the CD2 subset of the immunoglobulin superfamily.

The molecular classification of multiple myeloma

P304

4309-4318

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2008-10-183772

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

113

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-02-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23983021

http://www.w3.org/2001/XMLSchema#string

P698

19196658

http://www.w3.org/2001/XMLSchema#string

P932

2676088

http://www.w3.org/2001/XMLSchema#string